Lonza continues to develop its industrial operations in Switzerland and abroad. In Visp, the group plans to expand its production capacity for innovative medicines, particularly cancer treatments that target diseased cells more precisely. New facilities are expected to be completed by 2028. Meanwhile, the group announced the acquisition of five production sites in the United States, which employ around 1,100 people. These two projects highlight the group’s ambitions for growth and the importance of Valais within its global industrial network.
New facilities in Visp expected by 2028
Lonza continues to invest in its Visp site to meet growing demand for innovative medicines, particularly certain cancer treatments. The project involves modernising existing facilities and constructing a new production unit. The first phase is expected to be completed in 2027, with new equipment that will allow Lonza to produce and purify medicines more flexibly and meet the needs of different clients.
Starting in 2028, three new production units are expected to become operational. These facilities will enable the manufacture of different types of medicines and allow production volumes to increase gradually. Lonza will therefore be able to support its clients in the development of their medicines, from the early stages of clinical trials through to commercialisation. These investments strengthen the position of the Visp site within Lonza’s global production network.
Lonza expands its presence in the United States
Several days after the announcement of its investments in Visp, Lonza announced an agreement to acquire five pharmaceutical production sites owned by the German group Merck.
Located across several US states, these sites offer complementary expertise in the development and manufacturing of innovative treatments. They bring expertise in the manufacture of complex medicines, including certain cancer treatments, as well as technologies for developing and producing new medicines. The transaction will increase Lonza’s number of production sites in the United States from four to nine and add around 1,100 employees to its workforce.
This acquisition, which is expected to be completed by mid-2027, is in line with the group’s ambition to strengthen its presence on the US pharmaceutical market and broaden the range of services it offers its clients.
Visp, a key link in Lonza’s global network
By strengthening its facilities in Visp while expanding its network in the United States, Lonza confirms the importance of the Valais-based site as part of its international strategy. The Visp site contributes to the development and production of innovative medicines intended for patients worldwide. These investments also illustrate Valais’ industrial and scientific expertise and its contribution to the production of medicines for global markets.
Source: BioArk
Foto ©: Lonza
